Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vosaroxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vosaroxin SCHEMBL15933161 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL3207291 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL195037 | 1.00 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824841 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824869 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL7824853 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL18694851 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| Vosaroxin SCHEMBL29914037 | 0.99 | HTR3A (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| SCHEMBL15929815 | 0.94 | HTR3A (0.36) | HTR3AKMT2AALDH1A1PPARGMAPK10 | |
| SCHEMBL7836101 | 0.90 | ALDH1A1 (0.35) | HTR3AKMT2AALDH1A1PPARGMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1007 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | claimed |
| WO-2025043187-A1 | FIXED DOSE COMBINATIONS OF CEDAZURIDINE AND AZACITIDINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-27 | — | — | WO | claimed |
| WO-2025031307-A1 | MULTIDRUG LINKER AND ANTIBODY-DRUG CONJUGATE | 上海华藕生物医药有限公司 | 2025-02-13 | — | — | WO | claimed |
| CN-119072303-A | Combined preparation of sitagliptin | 大塚制药株式会社 | 2024-12-03 | — | — | CN | claimed |
| WO-2009054935-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-2049109-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND CYTARABINE (ARA-C) FOR THE TREATMENT OF LEUKEMIA | Sunesis Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2043645-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | Sunesis Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| EP-1931339-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | Sunesis Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| US-20080063642-A1 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders | SUNESIS PHARMACEUTICALS, INC. | 2008-03-13 | — | — | US | claimed |
| WO-2008016702-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| WO-2008016678-A2 | PHARMACEUTICAL DOSAGE FORMS FOR (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| WO-2007146335-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007028171-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20060247267-A1 | Voreloxin( SNS-595 ) and methanesulfonic acid ( for adjusting ph acidic) as anticarcinogenic agent | SUNESIS PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HTR3A 3482/4885KMT2A 2938/4885ALDH1A1 781/4885 |
| US-20080063642-A1 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders | MPL, PAICS, CD47 | HTR3A 1042/4885KMT2A 2487/4885ALDH1A1 388/4885 |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | HTR3A 1136/4885KMT2A 1634/4885ALDH1A1 4240/4885 |
| US-20060247267-A1 | Voreloxin( SNS-595 ) and methanesulfonic acid ( for adjusting ph acidic) as anticarcinogenic agent | PRDX6, PRDX5, PRDX2 | HTR3A 2356/4885KMT2A 4380/4885ALDH1A1 3312/4885 |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | DCTD, EZH2, DUT | HTR3A 2788/4885KMT2A 400/4885ALDH1A1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.